1
|
Smith MA, Camp JD, Johansen AN, Strickland JC. Response-contingent cocaine increases the reinforcing effectiveness of social contact. Exp Clin Psychopharmacol 2024; 32:255-262. [PMID: 37707472 PMCID: PMC10937325 DOI: 10.1037/pha0000679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 09/15/2023]
Abstract
Epidemiological studies report a high concordance rate of drug use within groups, suggesting an interplay between drug reinforcement and social cohesion. Preclinical studies reveal that (a) contingent access to a social partner increases cocaine intake and (b) experimenter-delivered cocaine increases the reinforcing effects of social contact. The purpose of this study was to determine if response-contingent cocaine increases the reinforcing effectiveness of social contact. Male rats were implanted with intravenous catheters and trained on a fixed ratio (FR1) schedule for 30-s access to a social partner. The reinforcing effectiveness of social contact was then determined using a progressive ratio (PR) schedule. After the PR test, rats were divided into two groups in which each response on an FR1 schedule produced social access and either response-contingent cocaine (0.5 mg/kg/infusion) or saline. After 9 days, the reinforcing effectiveness of social contact in the absence of infusions was determined again on the PR schedule. The cocaine and saline reinforcers were then switched between groups and the latter procedures were repeated. Recent exposure to response-contingent cocaine increased the reinforcing effectiveness of social contact on the PR schedule. This effect was transient, and the reinforcing effectiveness of social contact returned to baseline levels once response-contingent cocaine was replaced with saline. These data indicate that recent exposure to response-contingent cocaine transiently increases the reinforcing effectiveness of social contact and suggest that cocaine use may strengthen social cohesion by increasing the reinforcing effects of social contact with other individuals. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
Collapse
Affiliation(s)
- Mark A Smith
- Department of Psychology and Program in Neuroscience, Davidson College
| | - Jacob D Camp
- Department of Psychology and Program in Neuroscience, Davidson College
| | | | - Justin C Strickland
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
| |
Collapse
|
2
|
Smith MA, Pearson T, Ballard SL, Camp JD, Sharp JL. The effects of gonadal hormones on heroin Self-Administration in male gonadectomized rats. Psychopharmacology (Berl) 2024; 241:171-179. [PMID: 37833541 PMCID: PMC11135215 DOI: 10.1007/s00213-023-06471-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Accepted: 09/23/2023] [Indexed: 10/15/2023]
Abstract
RATIONALE Previous studies have shown that gonadal hormones influence opioid self-administration in female rodents, but very few studies have examined these effects in male rodents. OBJECTIVES The purpose of this study was to examine the effects of chronic hormone treatment on intravenous heroin self-administration in gonadectomized male rats using both physiological and supraphysiological doses of testosterone, estradiol, or progesterone. METHODS Gonadectomized male rats were surgically implanted with intravenous catheters and trained to self-administer heroin on a fixed ratio (FR1) schedule of reinforcement. Using a between-subjects design, rats were treated daily with testosterone (0.175 or 1.75 mg, sc), estradiol (0.0005 or 0.005 mg, sc), progesterone, (0.0125 or 0.125 mg, sc), or their vehicles. After 14 days of chronic treatment, a dose-effect curve was determined for heroin (0.0003-0.03 mg/kg/infusion) over the course of one week. RESULTS Neither testosterone nor estradiol altered responding maintained by heroin. In contrast, the high dose of progesterone (0.125 mg) reduced responding maintained by all doses of heroin to saline-control levels. This dose of progesterone did not reduce responding maintained by food on a progressive ratio schedule in either food-restricted or food-sated rats. CONCLUSIONS These data indicate that exogenous progesterone or a pharmacologically active metabolite selectively decreases heroin intake in male rodents, which may have therapeutic implications for men with opioid use disorder.
Collapse
Affiliation(s)
- Mark A Smith
- Department of Psychology and Program in Neuroscience, Davidson College, Davidson, NC, USA.
| | - Tallia Pearson
- Department of Psychology and Program in Neuroscience, Davidson College, Davidson, NC, USA
| | - Shannon L Ballard
- Department of Psychology and Program in Neuroscience, Davidson College, Davidson, NC, USA
| | - Jacob D Camp
- Department of Psychology and Program in Neuroscience, Davidson College, Davidson, NC, USA
| | - Jessica L Sharp
- Department of Psychology and Program in Neuroscience, Davidson College, Davidson, NC, USA
| |
Collapse
|
3
|
Delage C, Morel A, de Witt P, Jauffret-Roustide M, Bloch V, Noble F, Vorspan F, Marie N. Behavioral sensitization to psychostimulants and opioids: What is known in rodents and what still needs to be explored in humans? Prog Neuropsychopharmacol Biol Psychiatry 2023; 127:110824. [PMID: 37479108 DOI: 10.1016/j.pnpbp.2023.110824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Revised: 06/28/2023] [Accepted: 07/07/2023] [Indexed: 07/23/2023]
Abstract
Repeated exposure to substances of abuse results in an increase in some behavioral responses. This phenomenon, called behavioral sensitization (BS), is well described in preclinical models. However, its existence in humans is still a matter of debate. After a review of preclinical evidence of BS and its mechanisms in animal models, we reviewed the evidence supporting the existence of BS in humans, despite the limited research available in this regard. We focused our review on opioids and psychostimulants, since they share the ability to promote addictive behaviors. Further, they induce BS despite their distinct sedative and stimulant properties. Moreover, we proposed future research perspectives in this review to address the remaining unsolved questions, especially regarding BS in humans using a harm reduction approach.
Collapse
Affiliation(s)
- Clément Delage
- Université Paris Cité, Inserm, UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, F-75006 Paris, France; Service Pharmacie, AP-HP, Hôpital Lariboisière-Fernand Widal, F-75010 Paris, France
| | - Alix Morel
- Département de Psychiatrie et de Médecine Addictologique, AP-HP, Hôpital Lariboisière-Fernand Widal, F-75010 Paris, France
| | - Pauline de Witt
- Département de Psychiatrie et de Médecine Addictologique, AP-HP, Hôpital Lariboisière-Fernand Widal, F-75010 Paris, France
| | - Marie Jauffret-Roustide
- École des hautes études en sciences sociales, Inserm U 1276, CNRS UMR 8044, Centre d'étude des mouvements sociaux, Paris, France
| | - Vanessa Bloch
- Université Paris Cité, Inserm, UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, F-75006 Paris, France; Service Pharmacie, AP-HP, Hôpital Lariboisière-Fernand Widal, F-75010 Paris, France
| | - Florence Noble
- Université Paris Cité, Inserm UMR-S1124, CNRS EMR 3649, "Pharmacologie et thérapies des addictions", Paris, France
| | - Florence Vorspan
- Université Paris Cité, Inserm, UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, F-75006 Paris, France; Département de Psychiatrie et de Médecine Addictologique, AP-HP, Hôpital Lariboisière-Fernand Widal, F-75010 Paris, France
| | - Nicolas Marie
- Université Paris Cité, Inserm UMR-S1124, CNRS EMR 3649, "Pharmacologie et thérapies des addictions", Paris, France.
| |
Collapse
|
4
|
Smith MA, Ballard SL, Ballesteros CF, Bonge SA, Casimir AT, Childs LM, Feinstein MA, Griffith AK, Johansen AN, Lee D, Mauser AC, Moses CM, Robertson IJ, Robles JU, Strickland JC, Walters ME, Yoo SJ. Interactions Between Opioids and Dextroamphetamine on Locomotor Activity: Influence of an Opioid's Relative Efficacy at the Mu Receptor. Front Psychiatry 2021; 12:790471. [PMID: 35069292 PMCID: PMC8766790 DOI: 10.3389/fpsyt.2021.790471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Accepted: 12/08/2021] [Indexed: 11/16/2022] Open
Abstract
Opioids and stimulants are often used in combination for both recreational and non-recreational purposes. High-efficacy mu opioid agonists generally increase the behavioral effects of stimulants, whereas opioid receptor antagonists generally attenuate the behavioral effects of stimulants; however, less is known regarding the interactions between stimulants and opioids possessing low to intermediate efficacy at the mu receptor. The purpose of this study was to examine the role of an opioid's relative efficacy at the mu receptor in altering the behavioral effects of dextro(d-)amphetamine. To this end, opioids possessing a range of relative efficacy at the mu receptor were examined alone and in combination with cumulative doses of d-amphetamine on a test of open-field, locomotor activity in male rats. Levorphanol, buprenorphine, butorphanol, nalbuphine, (-)-pentazocine, (-)-metazocine, (-)-cyclazocine, (-)-NANM, and nalorphine increased the locomotor effects of d-amphetamine in either an additive or greater-than-additive manner according to an effect-additive model. Only the selective, high-efficacy kappa agonist, spiradoline, and the non-selective opioid receptor antagonist, naloxone, failed to increase the effects of d-amphetamine under the conditions examined. These data indicate that opioids possessing a large range of relative efficacy at the mu receptor, including those possessing very low relative efficacy, significantly increase the locomotor effects of d-amphetamine.
Collapse
Affiliation(s)
- Mark A Smith
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Shannon L Ballard
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Clarise F Ballesteros
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Samantha A Bonge
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Alexander T Casimir
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Lauren M Childs
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Max A Feinstein
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Annie K Griffith
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Alexandra N Johansen
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Daegeon Lee
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - A Caroline Mauser
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Cassidy M Moses
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Ian J Robertson
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Javier U Robles
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Justin C Strickland
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Mary E Walters
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Seeley J Yoo
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| |
Collapse
|
5
|
Zjawiony JK, Machado AS, Menegatti R, Ghedini PC, Costa EA, Pedrino GR, Lukas SE, Franco OL, Silva ON, Fajemiroye JO. Cutting-Edge Search for Safer Opioid Pain Relief: Retrospective Review of Salvinorin A and Its Analogs. Front Psychiatry 2019; 10:157. [PMID: 30971961 PMCID: PMC6445891 DOI: 10.3389/fpsyt.2019.00157] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2018] [Accepted: 03/04/2019] [Indexed: 12/21/2022] Open
Abstract
Over the years, pain has contributed to low life quality, poor health, and economic loss. Opioids are very effective analgesic drugs for treating mild, moderate, or severe pain. Therapeutic application of opioids has been limited by short and long-term side effects. These side effects and opioid-overuse crisis has intensified interest in the search for new molecular targets and drugs. The present review focuses on salvinorin A and its analogs with the aim of exploring their structural and pharmacological profiles as clues for the development of safer analgesics. Ethnopharmacological reports and growing preclinical data have demonstrated the antinociceptive effect of salvinorin A and some of its analogs. The pharmacology of analogs modified at C-2 dominates the literature when compared to the ones from other positions. The distinctive binding affinity of these analogs seems to correlate with their chemical structure and in vivo antinociceptive effects. The high susceptibility of salvinorin A to chemical modification makes it an important pharmacological tool for cellular probing and developing analogs with promising analgesic effects. Additional research is still needed to draw reliable conclusions on the therapeutic potential of salvinorin A and its analogs.
Collapse
Affiliation(s)
- Jordan K Zjawiony
- Division of Pharmacognosy, Department of BioMolecular Sciences, School of Pharmacy, Research Institute of Pharmaceutical Sciences, University of Mississippi, University, MS, United States
| | - Antônio S Machado
- Laboratory of Medicinal Pharmaceutical Chemistry, Faculty of Pharmacy, Universidade Federal de Goiás, Goiânia, Brazil
| | - Ricardo Menegatti
- Laboratory of Medicinal Pharmaceutical Chemistry, Faculty of Pharmacy, Universidade Federal de Goiás, Goiânia, Brazil
| | - Paulo C Ghedini
- Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Goiás, Goiânia, Brazil
| | - Elson A Costa
- Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Goiás, Goiânia, Brazil
| | - Gustavo R Pedrino
- Department of Physiology, Universidade Federal de Goiás, Goiânia, Brazil
| | - Scott E Lukas
- McLean Imaging Center, Harvard Medical School, McLean Hospital, Belmont, MA, United States
| | - Octávio L Franco
- S-Inova Biotech, Programa de Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande, Brazil.,Centro de Análises Proteômicas e Bioquímicas, Pós-graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, Brazil.,Programa de Pós-graduação em Patologia Molecular, Universidade de Brasília, Brasília, Brazil
| | - Osmar N Silva
- S-Inova Biotech, Programa de Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande, Brazil
| | - James O Fajemiroye
- Department of Physiology, Universidade Federal de Goiás, Goiânia, Brazil.,Centro Universitário de Anápolis, Unievangélica, Anápolis, Brazil
| |
Collapse
|
6
|
Chen SR, Ke YY, Yeh TK, Lin SY, Ou LC, Chen SC, Chang WT, Chang HF, Wu ZH, Hsieh CC, Law PY, Loh HH, Shih C, Lai YK, Yeh SH, Ueng SH. Discovery, structure-activity relationship studies, and anti-nociceptive effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)benzamides as novel opioid receptor agonists. Eur J Med Chem 2016; 126:202-217. [PMID: 27776274 DOI: 10.1016/j.ejmech.2016.09.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2016] [Revised: 08/28/2016] [Accepted: 09/01/2016] [Indexed: 10/21/2022]
Abstract
μ-Opioid receptor (MOR) agonists are analgesics used clinically for the treatment of moderate to severe pain, but their use is associated with severe adverse effects such as respiratory depression, constipation, tolerance, dependence, and rewarding effects. In this study, we identified N-({2-[(4-bromo-2-trifluoromethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-1-isoquinolinyl}methyl)cyclohexanecarboxamide (1) as a novel opioid receptor agonist by high-throughput screening. Structural modifications made to 1 to improve potency and blood-brain-barrier (BBB) penetration resulted in compounds 45 and 46. Compound 45 was a potent MOR/KOR (κ-opioid receptor) agonist, and compound 46 was a potent MOR and medium KOR agonist. Both 45 and 46 demonstrated a significant anti-nociceptive effect in a tail-flick test performed in wild type (WT) B6 mice. The ED50 value of 46 was 1.059 mg/kg, and the brain concentrations of 45 and 46 were 7424 and 11696 ng/g, respectively. Accordingly, compounds 45 and 46 are proposed for lead optimization and in vivo disease-related pain studies.
Collapse
Affiliation(s)
- Sheng-Ren Chen
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan; Institute of Biotechnology and Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan
| | - Yi-Yu Ke
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan
| | - Teng-Kuang Yeh
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan
| | - Shu-Yu Lin
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan
| | - Li-Chin Ou
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan
| | - Shu-Chun Chen
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan
| | - Wan-Ting Chang
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan
| | - Hsiao-Fu Chang
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan
| | - Zih-Huei Wu
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan
| | - Chih-Chien Hsieh
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan
| | - Ping-Yee Law
- Department of Pharmacology, University of Minnesota, Medical School, Minneapolis, MN, 55455, USA
| | - Horace H Loh
- Department of Pharmacology, University of Minnesota, Medical School, Minneapolis, MN, 55455, USA
| | - Chuan Shih
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan
| | - Yiu-Kay Lai
- Institute of Biotechnology and Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan.
| | - Shiu-Hwa Yeh
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan; The PhD Program for Neural Regenerative Medicine, Taipei Medical University, Taipei, 110, Taiwan.
| | - Shau-Hua Ueng
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 35053, Taiwan.
| |
Collapse
|
7
|
Abstract
Advances in neuroscience identified addiction as a chronic brain disease with strong genetic, neurodevelopmental, and sociocultural components. We here discuss the circuit- and cell-level mechanisms of this condition and its co-option of pathways regulating reward, self-control, and affect. Drugs of abuse exert their initial reinforcing effects by triggering supraphysiologic surges of dopamine in the nucleus accumbens that activate the direct striatal pathway via D1 receptors and inhibit the indirect striato-cortical pathway via D2 receptors. Repeated drug administration triggers neuroplastic changes in glutamatergic inputs to the striatum and midbrain dopamine neurons, enhancing the brain's reactivity to drug cues, reducing the sensitivity to non-drug rewards, weakening self-regulation, and increasing the sensitivity to stressful stimuli and dysphoria. Drug-induced impairments are long lasting; thus, interventions designed to mitigate or even reverse them would be beneficial for the treatment of addiction.
Collapse
Affiliation(s)
- Nora D Volkow
- National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA.
| | - Marisela Morales
- National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA
| |
Collapse
|
8
|
Abstract
This paper is the thirty-sixth consecutive installment of the annual review of research concerning the endogenous opioid system. It summarizes papers published during 2013 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides, opioid receptors, opioid agonists and opioid antagonists. The particular topics that continue to be covered include the molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors related to behavior, and the roles of these opioid peptides and receptors in pain and analgesia; stress and social status; tolerance and dependence; learning and memory; eating and drinking; alcohol and drugs of abuse; sexual activity and hormones, pregnancy, development and endocrinology; mental illness and mood; seizures and neurologic disorders; electrical-related activity and neurophysiology; general activity and locomotion; gastrointestinal, renal and hepatic functions; cardiovascular responses; respiration and thermoregulation; and immunological responses.
Collapse
Affiliation(s)
- Richard J Bodnar
- Department of Psychology and Neuropsychology Doctoral Sub-Program, Queens College, City University of New York, Flushing, NY 11367, United States.
| |
Collapse
|
9
|
Cheng MF, Ou LC, Chen SC, Chang WT, Law PY, Loh HH, Chao YS, Shih C, Yeh SH, Ueng SH. Discovery, structure–activity relationship studies, and anti-nociceptive effects of 1-phenyl-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one as novel opioid receptor agonists. Bioorg Med Chem 2014; 22:4694-703. [DOI: 10.1016/j.bmc.2014.07.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2014] [Revised: 07/07/2014] [Accepted: 07/08/2014] [Indexed: 11/26/2022]
|
10
|
Bidlack JM. Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 2014; 69:387-418. [PMID: 24484983 DOI: 10.1016/b978-0-12-420118-7.00010-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Cocaine use activates the dopamine reward pathway, leading to the reinforcing effects of dopamine. There is no FDA-approved medication for treating cocaine dependence. Opioid agonists and antagonists have been approved for treating opioid and alcohol dependence. Agonists that activate the μ opioid receptor increase dopamine levels in the nucleus accumbens, while μ receptor antagonists decrease dopamine levels by blocking the effects of endogenous opioid peptides. Activation of the κ opioid receptor decreases dopamine levels and leads to dysphoria. In contrast, inhibition of the κ opioid receptor decreases dopamine levels in the nucleus accumbens. Antagonists acting at the κ receptor reduce stress-mediated behaviors and anxiety. Mixed partial μ/κ agonists have the potential of striking a balance between dopamine levels and attenuating relapse to cocaine. The pharmacological properties of mixed μ/κ opioid receptor agonists will be discussed and results from clinical and preclinical studies will be presented. Results from studies with some of the classical benzomorphans and morphinans will be presented as they lay the foundation for structure-activity relationships. Recent results with other partial opioid agonists, including buprenorphine derivatives and the mixed μ/κ peptide CJ-15,208, will be discussed. The behavioral effects of the mixed μ/κ MCL-741, an aminothiazolomorphinan, in attenuating cocaine-induced locomotor activity will be presented. While not a mixed μ/κ opioid, results obtained with GSK1521498, a μ receptor inverse agonist, will be discussed. Preclinical strategies and successes will lay the groundwork for the further development of mixed μ/κ opioid receptor agonists to treat cocaine dependence.
Collapse
Affiliation(s)
- Jean M Bidlack
- School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA.
| |
Collapse
|
11
|
Provencher BA, Sromek AW, Li W, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors. J Med Chem 2013; 56:8872-8. [PMID: 24107104 DOI: 10.1021/jm401290y] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Previous studies with aminothiazolomorphinans suggested that this class of opioid ligands may be useful as a potential pharmacotherapeutic to decrease drug abuse. Novel aminothiazole derivatives of cyclorphan were prepared to evaluate a series of aminothiazolomorphinans with varying pharmacological properties at the κ opioid receptor (KOR) and μ opioid receptor (MOR). This study was focused on exploring the regioisomeric analogs with the aminothiazole on the C-ring of the morphinan skeleton. Receptor binding and [(35)S]GTPγS binding assays were used to characterize the affinity and pharmacological properties of the aminothiazolomorphinans. Intracranial self-stimulation (ICSS) was used to compare the effects of a representative aminothiazolomorphinan with the morphinan mixed-KOR/MOR agonist butorphan (MCL-101) on brain-stimulation reward.
Collapse
Affiliation(s)
- Brian A Provencher
- Alcohol & Drug Abuse Research Center, ‡Mailman Research Center, McLean Hospital, Harvard Medical School , 115 Mill Street, Belmont, Massachusetts 02478, United States
| | | | | | | | | | | | | | | |
Collapse
|